Bifidobacterium breve
Useful mainly for preterm infants (NEC prevention) and infant GI/allergy support, strain-dependent and supervised.
Quick decision guide
May help most
preterm infants (NEC prevention) and infant GI/allergy support, strain-dependent and supervised
Common dosing range
Infants ~0.1–10 billion CFU/day; adults 1–20 billion CFU/dose
When to expect effects
Weeks (consistency matters)
Watch out for
Avoid live probiotics in critically ill or severely immunocompromised people without specialist input
What is it
Bifidobacterium breve is a probiotic bacterium naturally present in the gut of breastfed infants and, in lower amounts, in adults. It is used in probiotic supplements for infant and pediatric digestive health, allergic conditions, and immune support.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
cognitive function (strain a1) Limited Evidence | Small / uncertain | older adults studied with the specific A1 strain | Weeks to months |
infant colic and functional gi symptoms Mixed Evidence | Modest / uncertain | infants with colic or functional GI symptoms, strain-matched | Weeks |
cognitive function (strain a1)
- Effect
- Small / uncertain
- Best fit
- older adults studied with the specific A1 strain
- Time
- Weeks to months
infant colic and functional gi symptoms
- Effect
- Modest / uncertain
- Best fit
- infants with colic or functional GI symptoms, strain-matched
- Time
- Weeks
Evidence for 2 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
cognitive function (strain a1)
Supplement benefitB. breve strain A1 has been studied for cognitive outcomes in adults via the gut–brain axis, with some small trials reporting benefit. The data are limited, strain-specific, and not yet replicated broadly. Effects should not be assumed for other B. breve strains.
Bottom line: Early, strain-A1-specific signal for cognition that needs more replication before any confidence.
infant colic and functional gi symptoms
Supplement benefitB. breve produces lactate and acetate, lowers colonic pH, and may influence motility, providing a rationale for use in infant colic and functional GI symptoms. Clinical evidence is limited and strain-specific, and much colic probiotic data centers on other species. Benefit for B. breve specifically is preliminary.
Bottom line: Plausible but preliminary for infant colic; strain-specific data are limited.
How it works
How to take it
What to track
3 commercial forms
Compare the main delivery options and what they’re best suited for.
B. breve M-16V (BBG-001)
Most-studied strain for neonatal applications. Used in NICU probiotic protocols in some countries.
Acid-stable, well-studied in preterm infants
B. breve A1
Developed for memory and cognitive outcomes in older adults.
Studied for cognitive applications
B. breve BR-03
Used in commercial adult and pediatric probiotic formulations.
Common in multi-strain blends
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Probiotic bacteremia in critically ill or extremely premature infants and immunocompromised adults
Who should avoid it
- Severely immunocompromised individuals
- People with central venous catheters
- Critically ill patients without physician oversight
Pregnancy & breastfeeding
Generally well tolerated in pregnancy and breastfeeding.
Interactions
Can kill the probiotic; separate doses by at least 2 hours
May slightly increase risk of bacterial translocation
Food sources
| Food | Amount | %DV |
|---|---|---|
| Some infant formulas with added Bifidobacterium | Variable; check label | — |
| Yogurts with added Bifidobacterium | Variable; B. breve specifically uncommon | — |
| Human breast milk (natural source) | Natural transmission to infant gut | — |
Some infant formulas with added Bifidobacterium
- Amount
- Variable; check label
- %DV
- —
Yogurts with added Bifidobacterium
- Amount
- Variable; B. breve specifically uncommon
- %DV
- —
Human breast milk (natural source)
- Amount
- Natural transmission to infant gut
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Why is B. breve common in infant probiotics?⌄
B. breve naturally dominates the gut of breastfed infants and is well adapted to metabolize human milk oligosaccharides. This makes it a logical choice for infant-targeted formulations.
Should I give B. breve to my preterm baby?⌄
Probiotic use in preterm infants should only occur under specialist neonatal supervision. Some NICUs use protocols including B. breve, but this is not appropriate for parents to start independently.
Does B. breve help adults?⌄
Most B. breve research has focused on infants, but some adult trials (particularly with strain A1) explore cognitive and digestive applications. Evidence in adults is less extensive than in infants.
Can B. breve survive the adult stomach?⌄
Modern supplement-grade strains are selected for acid tolerance, and some are delivered in protective capsules. A meaningful fraction of cells typically reaches the colon alive.
How long until I see effects?⌄
For acute applications, effects may appear within days. For chronic concerns or in infants with colic, allow several weeks of consistent use.
References by claim
Track Bifidobacterium breve with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.